Aung Naing

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

David S. Hong, Razelle Kurzrock, Aung Naing et al. · Investigational New Drugs · 2013 · 205 citations

Dose-escalation Study, Tumor Biology, Splicesome Inhibitor +10

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2022 · 23 citations

Parallel Evaluation, Mixed-phenotype Acute Leukemia, Immunology +16

Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.

Russell J. Schilder, John D. Powderly, Haeseong Park et al. · Journal of Clinical Oncology · 2022 · 18 citations

Icatolimab Monotherapy, Immunology, Immunoediting +20

Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer

Mehmet Altan, Felipe Soto, Ting Xu et al. · Clinical Oncology · 2023 · 17 citations

Medicine, Immunology, Concurrent Chemoradiation +7

A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.

Gerald S. Falchook, Jennifer J. Wheler, Aung Naing et al. · Journal of Clinical Oncology · 2010 · 12 citations

Medicine, Pharmacology, Immunology +7